COLLAGEN BIOSYNTHESIS IN HUMAN SKIN FIBROBLASTS
人类皮肤成纤维细胞中的胶原蛋白生物合成
基本信息
- 批准号:2683262
- 负责人:
- 金额:$ 16.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1981
- 资助国家:美国
- 起止时间:1981-04-01 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Collagen is a major component of connective tissue. Its synthesis is
altered in many disease processes, increasing in fibrotic conditions and
abnormal scarring and decreasing in impaired wound healing. The proposed
studies are aimed at understanding the molecular mechanisms responsible
for: (1) Inhibition of collagen synthesis by benzoic hydrazide; and (2)
inhibition of lysyl hydroxylase expression by minoxidil. Among the
parameters that will be studied are type-specific collagen synthesis,
procollagen mRNA stability, procollagen gene transcription and
posttranslational modifying enzymes prolyl hydroxylase and lysyl
hydroxylase. Transcriptional mechanisms will be explored with chimeric
genes containing promoter sequences for collagen or lysyl hydroxylase
genes linked to appropriate reporter genes. These genes will be inserted
into fibroblasts to examine influences on promoter activity. The eventual
goal of this research is to identify regulatory molecules and to define
the nature of their interaction with genes enabling us to design
additional effector molecules that can modulate gene expression. An
understanding of the transcriptional effects of minoxidil or benzoic
hydrazide may lead to effective strategies for controlling excessive
collagen accumulation in fibrotic conditions.
胶原蛋白是结缔组织的主要成分。它的合成是
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHELDON R PINNELL其他文献
SHELDON R PINNELL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHELDON R PINNELL', 18)}}的其他基金
Photoprotection of Skin by Novel Polyphenol Antioxidants
新型多酚抗氧化剂对皮肤的光保护
- 批准号:
6691497 - 财政年份:2003
- 资助金额:
$ 16.35万 - 项目类别:
CHARACTERIZATION OF GENES FOR HUMAN TYPE I COLLAGEN
人类 I 型胶原蛋白基因的表征
- 批准号:
3152320 - 财政年份:1983
- 资助金额:
$ 16.35万 - 项目类别:
COLLAGEN BIOSYNTHESIS IN HUMAN SKIN FIBROBLASTS
人类皮肤成纤维细胞中的胶原蛋白生物合成
- 批准号:
3151876 - 财政年份:1981
- 资助金额:
$ 16.35万 - 项目类别:
COLLAGEN BIOSYNTHESIS IN HUMAN SKIN FIBROBLASTS
人类皮肤成纤维细胞中的胶原蛋白生物合成
- 批准号:
3155633 - 财政年份:1981
- 资助金额:
$ 16.35万 - 项目类别:
COLLAGEN BIOSYNTHESIS IN HUMAN SKIN FIBROBLASTS
人类皮肤成纤维细胞中的胶原蛋白生物合成
- 批准号:
2899834 - 财政年份:1981
- 资助金额:
$ 16.35万 - 项目类别:
相似海外基金
Antimetabolites Effective against Resistant Gram-positive Bacteria
抗代谢药可有效对抗耐药革兰氏阳性细菌
- 批准号:
8705774 - 财政年份:2014
- 资助金额:
$ 16.35万 - 项目类别:
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
一线抗代谢药物作为类固醇节约治疗 (FAST) 葡萄膜炎试验
- 批准号:
8549253 - 财政年份:2012
- 资助金额:
$ 16.35万 - 项目类别:
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
一线抗代谢药物作为类固醇节约治疗 (FAST) 葡萄膜炎试验
- 批准号:
8724947 - 财政年份:2012
- 资助金额:
$ 16.35万 - 项目类别:
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
一线抗代谢药物作为类固醇节约治疗 (FAST) 葡萄膜炎试验
- 批准号:
8266928 - 财政年份:2012
- 资助金额:
$ 16.35万 - 项目类别: